^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PRTH-101

    i
    Other names: PRTH-101
    Associations

    News

    Trials
    Company:
    Incendia Therap
    Drug class:
    DDR1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies (ESMO 2023)
    Safety, efficacy, pharmacokinetic, and pharmacodynamic endpoints will be monitored and reported. DDR1 expression levels on tumors, circulating DDR1, molecular and cellular changes in the TME, and changes on CD8 PET imaging will also be assessed.
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8)
    |
    Keytruda (pembrolizumab) • PRTH-101
    over1year
    A highly selective humanized DDR1 mAb reverses immune exclusion by disrupting collagen fiber alignment in breast cancer. (PubMed, J Immunother Cancer)
    This study not only paves a pathway for the development of PRTH-101 as a cancer therapeutic, but also sheds light on a new therapeutic strategy to modulate collagen alignment in the tumor ECM for enhancing antitumor immunity.
    Journal
    |
    PRTH-101